These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 773300)

  • 1. Bactericidal action of dapsone against Mycobacterium leprae in mice.
    Levy L
    Antimicrob Agents Chemother; 1976 Apr; 9(4):614-7. PubMed ID: 773300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility of Mycobacterium leprae to dapsone as a determinant of patient response to acedapsone.
    Levy L; Peters JH
    Antimicrob Agents Chemother; 1976 Jan; 9(1):102-12. PubMed ID: 769667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viability of Mycobacterium leprae after multiplication in mice.
    Welch TM; Gelber RH; Murray LP; Ng H; O'Neill SM; Levy L
    Infect Immun; 1980 Nov; 30(2):325-8. PubMed ID: 7002795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Some characteristics of the action of dapsone on multiplication of Mycobacterium leprae in the mouse.
    Levy L; Peters JH
    Lepr Rev; 1977 Dec; 48(4):237-45. PubMed ID: 400808
    [No Abstract]   [Full Text] [Related]  

  • 5. Activity of ofloxacin against Mycobacterium leprae in the mouse.
    Grosset JH; Guelpa-Lauras CC; Perani EG; Beoletto C
    Int J Lepr Other Mycobact Dis; 1988 Jun; 56(2):259-64. PubMed ID: 3045223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of strains of Mycobacterium leprae isolated prior to 1977 from patients with previously untreated lepromatous leprosy.
    Shepard CC; Rees RJ; Levy L; Pattyn SR; Baohong J; Dela Cruz EC
    Int J Lepr Other Mycobact Dis; 1986 Mar; 54(1):11-5. PubMed ID: 3519796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of thymectomized and irradiated mice to challenge with several organisms and the effect of dapsone on infection with Mycobacterium leprae.
    Levy L; Ng H; Evans MJ; Krahenbuhl JL
    Infect Immun; 1975 May; 11(5):1122-32. PubMed ID: 804443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined rifampin and dapsone chemotherapy of Mycobacterium leprae infection of the neonatally thymectomized Lewis rat.
    Fieldsteel AH; Levy L
    Int J Lepr Other Mycobact Dis; 1980 Sep; 48(3):267-76. PubMed ID: 7002811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary dapsone resistance in leprosy.
    Vaishnavi C; Ganguly NK; Kumar B; Kaur S; Chakravarti RN
    Indian J Lepr; 1985; 57(3):507-13. PubMed ID: 3913705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary dapsone-resistant leprosy in Cebu, Philippines.
    Guinto RS; Cellona RV; Fajardo TT; de la Cruz EC
    Int J Lepr Other Mycobact Dis; 1981 Dec; 49(4):427-30. PubMed ID: 7042607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of ascorbic acid in inhibiting the multiplication of M. leprae in the mouse foot pad.
    Hastings RC; Richard V; Christy SA; Morales MJ
    Int J Lepr Other Mycobact Dis; 1976; 44(4):427-30. PubMed ID: 798727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clarithromycin is bactericidal against strains of Mycobacterium leprae resistant and susceptible to dapsone and rifampin.
    Walker LL; Van Landingham RM; Shinnick TM
    Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):59-65. PubMed ID: 8326182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapsone chemotherapy of Mycobacterium leprae infection of the neonatally thymectomized Lewis rat.
    Fieldsteel AH; Levy L
    Am J Trop Med Hyg; 1976 Nov; 25(6):854-9. PubMed ID: 795312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin.
    Matsuoka M; Kashiwabara Y; Namisato M
    Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):452-5. PubMed ID: 11332288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with dapsone, against Mycobacterium leprae.
    Dhople AM
    Int J Antimicrob Agents; 2002 Jan; 19(1):71-4. PubMed ID: 11814771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superiority of the neonatally thymectomized Lewis rat (NTLR) to monitor a clinical trial in lepromatous leprosy of the two regimens of rifampin and dapsone.
    Gelber RH; Humphres RC; Fieldsteel AH
    Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):273-83. PubMed ID: 3522770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo effects of N-methyl-3,5-dichloro-benzylamine hydrochloride on Mycobacterium leprae.
    Dhople AM; Strong LC; Meindl W; Schoenenberger H; Gardner GD
    Arzneimittelforschung; 1991 Mar; 41(3):253-6. PubMed ID: 1867663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of rifampicin and dapsone on experimental Mycobacterium leprae infections: minimum inhibitory concentrations and bactericidal action.
    Holmes IB; Hilson GR
    J Med Microbiol; 1972 May; 5(2):251-61. PubMed ID: 4555734
    [No Abstract]   [Full Text] [Related]  

  • 19. Minimal inhibitory concentration of dapsone for Mycobacterium leprae in rats.
    Peters JH; Gordon GR; Murray JF; Fieldsteel AH; Levy L
    Antimicrob Agents Chemother; 1975 Nov; 8(5):551-7. PubMed ID: 1108776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo activity of K-130, a dihydrofolate reductase inhibitor, against Mycobacterium leprae.
    Dhople AM
    Arzneimittelforschung; 1999 Mar; 49(3):267-71. PubMed ID: 10219472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.